Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw–like disease in mice

Abstract

Patients on high-dose bisphosphonate and immunosuppressive therapy have an increased risk of bisphosphonate-related osteonecrosis of the jaw (BRONJ); despite the disease severity, its pathophysiology remains unknown, and appropriate therapy is not established. Here we have developed a mouse model of BRONJ-like disease that recapitulates major clinical and radiographic manifestations of the human disease, including characteristic features of an open alveolar socket, exposed necrotic bone or sequestra, increased inflammatory infiltrates, osseous sclerosis, and radiopaque alveolar bone. We show that administration of zoledronate, a potent aminobisphosphonate, and dexamethasone, an immunosuppressant drug, causes BRONJ-like disease in mice in part by suppressing the adaptive regulatory T cells, Tregs, and activating the inflammatory T-helper-producing interleukin 17 cells, Th17. Most interestingly, we demonstrate that systemic infusion with mesenchymal stem cells (MSCs) prevents and cures BRONJ-like disease possibly via induction of peripheral tolerance, shown as an inhibition of Th17 and increase in Treg cells. The suppressed Tregs/Th17 ratio in zoledronate- and dexamethasone-treated mice is restored in mice undergoing salvage therapy with Tregs. These findings provide evidence of an immunity-based mechanism of BRONJ-like disease and support the rationale for in vivo immunomodulatory therapy using Tregs or MSCs to treat BRONJ. © 2010 American Society for Bone and Mineral Research

Shown for reading. Its publisher allows quoting it, not republishing it.

References 44

1. 1.

   Lipton A. New therapeutic agents for the treatment of bone diseases. Expert Opin Biol Ther. 2006;5:817-832.

   Not in our library10.1517/14712598.5.6.817

2. 2.

   Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719-3736.

   Not in our library10.1200/jco.2002.06.037

3. 3.

   Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082-1090.

   Not in our library10.1002/(sici)1097-0142(20000301)88:5<1082::aid-cncr20>3.0.co;2-z

4. 4.

   Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91:1191-1200.

   Not in our library10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0

5. 5.

   Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-1117.

   Not in our library10.1016/s0278-2391(03)00720-1

6. 6.

   American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-377.

   Not in our library10.1016/j.joms.2006.11.003

7. 7.

   Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res. 2007;86:1013-1021.

   Not in our library10.1177/154405910708601101

8. 8.

   Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2009;122:S33-S45.

   Not in our library10.1016/j.amjmed.2008.12.005

9. 9.

   Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update. Oral Oncol. 2009;45:301-308.

   Not in our library10.1016/j.oraloncology.2009.01.002

10. 10.

    Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032-1045.

    Not in our library10.4065/83.9.1032

11. 11.

    Cetiner S, Sucak GT, Kahraman SA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J Bone Miner Metab. 2009;27:435-443.

    Not in our library10.1007/s00774-009-0047-9

12. 12.

    Wimalawansa SJ. Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf. 2008;7:491-512.

    Not in our library10.1517/14740338.7.4.491

13. 13.

    Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-661.

    Not in our library10.1056/nejmoa011807

14. 14.

    Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580-8587.

    Not in our library10.1200/jco.2005.02.8670

15. 15.

    Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med. 2009;60:18.1-18.12.

    Not in our library10.1146/annurev.med.60.063007.134350

16. 16.

    Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ. 2003;327:469.

    Not in our library10.1136/bmj.327.7413.469

17. 17.

    Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-1575.

    Not in our library10.1016/j.joms.2005.07.010

18. 18.

    Kuehn BM. Reports of adverse events from bone drugs prompt caution. JAMA. 2006;295:2833-2836.

    Not in our library10.1001/jama.295.24.2833

19. 19.

    Wilkinson GS, Kuo Y-F, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A Population-Based Analysis. J Natl Cancer Inst. 2007;99:1016-1024.

    Not in our library10.1093/jnci/djm025

20. 20.

    Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-761.

    Not in our library10.7326/0003-4819-144-10-200605160-00009

21. 21.
    Pharmacologic Stem Cell Based Intervention as a New Approach to Osteoporosis Treatment in Rodents · 2008

    No notice
22. 22.

    Sun L, Akiyama K, Zhang H, et al. Mesenchymal Stem Cell Transplantation Reverses Multi-Organ Dysfunction in Systemic Lupus Erythematosus Mice and Humans. Stem Cells. 2009;27:1421-1432.

    Not in our library10.1002/stem.68

23. 23.

    Yamaza T, Miura Y, Akiyama K, et al. Mesenchymal stem cell-mediated ectopic hematopoiesis alleviates aging-related phenotype in immunocompromised mice. Blood. 2009;113:2595-2604.

    Not in our library10.1182/blood-2008-10-182246

24. 24.

    Khosla S, Burr D, Cauley J, American Society for Bone and Mineral Research, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-1491.

    Not in our library10.1359/jbmr.0707onj

25. 25.

    Wolf D, Wolf AM. Mesenchymal stem cells as cellular immunosuppressants. Lancet. 2008;371:1553-1554.

    Not in our library10.1016/s0140-6736(08)60666-2

26. 26.

    Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110:3499-3506.

    Not in our library10.1182/blood-2007-02-069716

27. 27.

    Oh JY, Kim MK, Shin MS, et al. The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells. 2008;26:1047-1055.

    Not in our library10.1634/stemcells.2007-0737

28. 28.

    Iyer SS, Rojas M. Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Exp Opin Biol Ther. 2008;8:569-581.

    Not in our library10.1517/14712598.8.5.569

29. 29.

    Wolf AM, Rumpold H, Tilg H, Gastl G, Gunsilius E, Wolf D. The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica. 2006;91:1165-1171.

    Not in our library

30. 30.

    Fiore F, Castella B, Nuschak B, et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood. 2007;110:921-927.

    Not in our library10.1182/blood-2006-09-044321

31. 31.

    Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007;67:11438-11446.

    Not in our library10.1158/0008-5472.can-07-1882

32. 32.

    Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol. 2009;45:164-172.

    Not in our library10.1016/j.oraloncology.2008.04.013

33. 33.

    Tang QZ, Bluestone JA. The Foxp 3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:239-944.

    Not in our library10.1038/ni1572

34. 34.

    Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775-787.

    Not in our library10.1016/j.cell.2008.05.009

35. 35.

    Awasthi A, Murugaiyan G, Kuchroo VK. Interplay between effector Th17 and regulatory T cells. J Clin Immunol. 2008;28:660-670.

    Not in our library10.1007/s10875-008-9239-7

36. 36.

    Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther. 2005;7:29-37.

    Not in our library10.1186/ar1478

37. 37.

    Harrinton LE, Hatton RD, Mangan PR, et al. Interleukin-17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-1132.

    Not in our library10.1038/ni1254

38. 38.

    Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature. 2006;441:235-238.

    Not in our library10.1038/nature04753

39. 39.

    Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol. 2006;6:329-333.

    Not in our library10.1038/nri1807

40. 40.

    Vernal R, Dutzan N, Chaparro A, Puente J, Antonieta Valenzuela M, Gamonal J. Levels of interleukin-17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from persons with chronic periodontitis. J Clin Periodontol. 2005;2:383-389.

    Not in our library10.1111/j.1600-051x.2005.00684.x

41. 41.

    Takahashi K, Azuma T, Motohira H, Kinane DF, Kitetsu S. The potential role of interleukin-17 in the immunopathology of periodontal disease. J Clin Periodontol. 2005;32:369-374.

    Not in our library10.1111/j.1600-051x.2005.00676.x

42. 42.

    Johnson RB, Wood N, Serio FG. Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. J Periodontol. 2004;75:37-43.

    Not in our library10.1902/jop.2004.75.1.37

43. 43.

    Hansen T, Kundel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006;35:155-160.

    Not in our library10.1111/j.1600-0714.2006.00391.x

44. 44.

    Hansen T, Kundel M, James Kirkpatrick C, Weber A. Actinomycosis in infected osteoradionecrosis: underestimated? Hum Pathol. 2006;37:61-67.

    Not in our library10.1016/j.humpath.2005.09.018

Cited by papers we hold 2

• Cell therapy stimulates bone neoformation in calvaria defects in rats subjected to local irradiation · 2019
  Not checked
• Stem cell-based bone and dental regeneration: a view of microenvironmental modulation · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.